Novo Nordisk wins Dutch court injunction enforcing semaglutide SPC against compounded nasal spray
NVO•Dutch court grants preliminary injunction
Novo Nordisk won a preliminary injunction in a Dutch patent case over a compounded semaglutide nasal spray sold by Ceban Ziekenhuisfarmacie.
The District Court of The Hague found infringement of Novo Nordisk’s supplementary protection certificate covering semaglutide.
Ceban was ordered to stop sales, remove product references, disclose supply-chain details, and pay Novo Nordisk’s legal costs.
The ruling targets an unapproved semaglutide nasal spray; Novo Nordisk’s marketed semaglutide brands are Wegovy, Ozempic and Rybelsus.
